Bharat Biotech successfully completes Phase III trials of new oral cholera vaccine Hillchol
Bharat Biotech successfully completes Phase III trials of new oral cholera vaccine Hillchol (Picture credit: X/@BharatBiotech)
HYDERABAD: Vaccine maker
Bharat Biotech
on Wednesday said its
oral cholera vaccine
,
Hillchol
, successfully completed
Phase III clinical trials
demonstrating efficacy against both
Ogawa and Inaba serotypes
.
The Hyderabad-based vaccine maker said Hillchol showed an over four-fold rise in vibriocidal antibodies—68.3% for Ogawa and 69.5% for Inaba serotypes.
The vaccine proved non-inferior to licensed vaccines and maintained a strong safety profile across all age groups, with only mild adverse events reported, it added.
The findings of the study have been published in the ScienceDirect vaccine journal.
The double-blind, randomised Phase III clinical trial was conducted to evaluate the safety, immunogenicity, non-inferiority, and lot-to-lot consistency of the single-component Hillchol in comparison to a comparator vaccine (Shanchol) in a diverse group of 1,800 individuals, ranging from infants to adults, across 10 clinical sites in India.
The study participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. The participants were randomised in a ratio of 3:1 to receive either Hillchol or a comparator vaccine.
Pointing to the significant role Hillchol can play in addressing the
global cholera crisis
and vaccine shortages, Bharat Biotech executive chairman Dr Krishna Ella said the new generation oral cholera vaccine features a simplified single stable O1 Hikojima strain, which enhances production efficiency and affordability and is particularly beneficial for lower- and middle-income countries.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Estrénalo con hasta 10 años de garantía
Nuevo Nissan Juke
Ver oferta
Undo
He said the company's facilities in Hyderabad and Bhubaneswar are equipped to produce 200 million doses of Hillchol and can ease the global shortage of oral cholera vaccines. While currently the global demand for oral cholera vaccines is around 100 million doses per annum, there is only one manufacturer, resulting in shortages.
Cholera, which is an acute diarrhoeal infection caused by ingesting food or water contaminated with vibrio cholerae bacteria, is estimated to cause over 2.86 million cases and around 95,000 deaths globally every year.
Bharat Biotech, which has delivered over nine billion doses of vaccines globally so far, has over 145 global patents and a portfolio of over 19 vaccines, four biotherapeutics and registrations in over 125 countries. Apart from developing India's first indigenous
Covid-19 vaccine Covaxin
, it has also developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (Jenvac), Rabies, Chikungunya, Zika, and the world's first tetanus-toxoid conjugated vaccine for Typhoid.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
18 minutes ago
- Mint
Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy
Zydus Lifesciences announced on Tuesday it is acquiring two biologics contract manufacturing facilities in California from US-based Agenus Inc for a total consideration of up to $125 million. The deal includes an upfront payment of $75 million, with the remaining $50 million to be paid over the following three years. The Ahmedabad-based pharmaceutical firm said the acquisition will establish its presence in the rapidly-expanding global biologics contract development and manufacturing organization (CDMO) sector. Zydus is also acquiring a 5.9% stake in Agenus for $16 million, through its wholly-owned subsidiary Zynext Ventures USA LLC, it said in an exchange filing on Tuesday. The drugmaker has also entered into a licensing agreement with Agenus to commercialise its investigational Botensilimab (BOT) and Balstilimab (BAL) combination therapy in India and Sri Lanka. Agenus is a clinical-stage immuno-oncology company committed to developing immune therapies against cancer. The move to acquire biologics manufacturing facilities in the US aligns with Zydus' strategic focus on biologics as a key growth driver this year. Also Read: Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial "The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California," managing director Sharvil Patel said in a statement. 'This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry," he added. Additionally, the acquisition gives the company a stronger manufacturing presence in the US, amid ongoing uncertainties over potential American tariffs on pharmaceutical imports. In the company's earnings call last month, Patel had said the company is evaluating opportunities for local manufacturing in the US. 'We have committed to making a good amount of investments in the US with our foray into specialty and other areas," he told investors. Exclusive manufacturer to Agenus Under the terms of the agreement, Zydus will acquire two modern biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and contingent payment of $50 million to be paid over three years subject to achievement of certain revenue milestone. The acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and a foothold in California, a leading global biotech hub. The move also enables Zydus to 'leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally," it said in the release. Also Read: KKR provides $600 mn financing to Manipal Group to fuel its corporate expansion The CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. As part of the transaction, Zydus will become the exclusive contract manufacturer for Agenus, and provide manufacturing services for the clinical and commercial supply of two identified Phase-3 ready immuno-oncology products - Botensilimab and Balstilimab. Zydus will also have the first right of negotiation to manufacture any of the future pipeline products by Agenus. Agenus reported a turnover of $103.46 million in 2024, according to the exchange filing. Agenus' lead programme comprising Botensilimab and Balstilimab is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. The platform, which is currently in advanced clinical trials, has demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and patients who have undergone neoadjuvant, or primary, therapy. As part of the licensing agreement inked with Agenus, Zydus will be responsible for clinical development and regulatory approvals of the licensed products in India and Sri Lanka and will pay 5% royalty on net sales upon successful approval and commercialization. Also Read: Young heirs take charge as Indian pharma firms plan succession Zydus will expand the reach of the therapy within its initial indications, as well as drive its expansion into other high unmet need indications and earlier lines of treatment, including primary treatments, the company said.
&w=3840&q=100)
Business Standard
29 minutes ago
- Business Standard
AI predicted to conduct deep scientific research and complex tasks by 2035
Mary Meeker and her team forecast that AI will generate hypotheses, design experiments and offer expert advice, while also creating films and operating robots within the next decade Aashish Aryan Delhi Artificial intelligence (AI) and AI-enabled tools are likely to be able to conduct deep scientific research by generating hypotheses, running simulations on the data obtained, designing and analysing experiments within the next 10 years, a report by Mary Meeker and her team has predicted. Meeker, often referred to as the 'mother of the internet', is the founder and general partner of San Francisco-based venture capital firm Bond Group. In their report, Meeker and her team have said that by 2035, AI and AI-enabled tools could discover materials, engineer biotech, prototype energy systems, manage research and development, finance and logistics of companies with minimal human input. Complex physical tasks such as handling tools, assembling components and adapting in real-world space, as well as offering expert-level decision-making, such as real-time legal, medical and business advice, will also be easily done by AI, the report predicts. In the near term, AI and AI-enabled tools will be able to create full-length films and games, generate scripts, characters, co-write novels, produce music, design architecture and operate humanoid robots by 2030. The report predicts that emotion-aware real-time multilingual agents, which understand and speak like human beings, will also be available to everyone in the next five years.
&w=3840&q=100)
Business Standard
29 minutes ago
- Business Standard
Sansera Engineering wins ₹160 crore Airbus deal for airborne ICT modules
Sansera Engineering Limited has signed a major long-term agreement with Airbus Defence and Space, valued at ₹160 crore (approximately $18.8 million). The Bengaluru-based precision engineering company will manufacture, supply and support airborne Intensive Care Transport Modules (ICTM) for Airbus' light and medium transport aircraft programmes. First Airbus ICTM contract awarded to an Indian supplier The ICTM is a vital medical evacuation system designed for transporting patients, including those in intensive care, during emergencies and health crises. It is a key component in defence and humanitarian missions. This is the first time Airbus has selected an Indian company to supply the ICTM kit, marking a significant milestone in both Sansera's global expansion and India's growing capabilities in aerospace manufacturing. The agreement covers complete manufacturing, delivery and ongoing support for the ICTM units. Sansera will carry out precision machining and structural assembly. It also marks the first formal partnership between Airbus and Sansera for such a specialised aerospace project in India. S Sekhar Vasan, Chairman and Managing Director of Sansera Engineering, said, 'I am proud to announce that Sansera has been selected as the Indian supply chain partner for Airbus, a leading global aerospace and defence company. This strategic partnership positions us as their trusted supplier for the Airborne Intensive Care Transport Module for light and medium transport aircraft programmes, marking a significant milestone in our journey as a precision manufacturing leader.' 'This achievement reflects decades of excellence in innovation, automation and quality that have established Sansera as a trusted name in the global aerospace supply chain and defence industry. It also strengthens the Hon'ble Prime Minister's Make in India initiative by establishing advanced aerospace manufacturing capabilities in India and supports the country's journey towards self-reliance in critical defence and aerospace technologies,' he added. In addition to aerospace and defence, Sansera Engineering is a key player in the automotive sector. The company manufactures essential components for engines, transmissions, braking systems, suspension and chassis across two-wheelers, passenger vehicles and commercial vehicles. Sansera also supplies critical parts to the semiconductor manufacturing industry, further diversifying its presence across high-tech and precision-driven sectors.
